Περίληψη:
The current study evaluated the differential expression detected in the
proteomic profiles of low risk- and high risk- ALL pediatric patients to
characterize candidate biomarkers related to diagnosis, prognosis and
patient targeted therapy. Bone marrow and peripheral blood plasma and
cell lysates samples were obtained from pediatric patients with low-
(LR) and high-risk (HR) ALL at diagnosis. As controls, non-leukemic
pediatric patients were studied. Cytogenetic analysis was carried out by
G- banding and interphase fluorescent in situ hybridization.
Differential proteomic analysis was performed using two-dimensional gel
electrophoresis and protein identification by matrix-assisted laser
desorption ionization time-of-flight mass spectrometry. The differential
expression of certain proteins was confirmed by Western blot analysis.
The obtained data revealed that CLUS, CERU, APOE, APOA4, APOA1, GELS,
S10A9, AMBP, ACTB, CATA and AFAM proteins play a significant role in
leukemia prognosis, potentially serving as distinctive biomarkers for
leukemia aggressiveness, or as suppressor proteins in HR-ALL cases. In
addition, vitronectin and plasminogen probably contributed to
leukemogenesis, whilst bicaudal D-related protein 1 could afford a
significant biomarker for pediatric ALL therapeutics.
Συγγραφείς:
Braoudaki, Maria
Lambrou, George I.
Vougas, Konstantinos and
Karamolegou, Kalliopi
Tsangaris, George T. and
Tzortzatou-Stathopoulou, Fotini
